{
  "source": "PA-Notification-Diabetes-Agents-GLP1-Receptor-Agonists.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1332-7\nProgram Prior Authorization/Notification: Diabetes Medications – GLP-1 & Dual\nGIP/GLP-1 Receptor Agonists\nMedication Bydureon BCise (exenatide extended-release), Byetta (exenatide),\nMounjaro (tirzepatide), Ozempic (semaglutide), Rybelsus (semaglutide),\nTrulicity (dulaglutide), Victoza (liraglutide)*\nP&T Approval Date 10/2020, 11/2021, 9/2022, 5/2023, 4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nByetta (exenatide), Ozempic (semaglutide), and Rybelsus (semaglutide) are indicated as an\nadjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\nBydureon BCise (exenatide extended-release), Trulicity (dulaglutide) and Victoza (liraglutide)*\nare indicated as an adjunct to diet and exercise to improve glycemic control in patients 10 years\nof age and older with type 2 diabetes mellitus. Ozempic, Trulicity and Victoza* are also\nindicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-\nfatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and\nestablished cardiovascular disease. Finally, Ozempic carries an additional indication to reduce\nthe risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults\nwith type 2 diabetes mellitus and chronic kidney disease.\nMounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and\nglucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to\nimprove glycemic control in adults with type 2 diabetes mellitus.\nBydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity and Victoza* are only\nindicated for the treatment of type 2 DM and are not FDA approved for the treatment of weight\nloss.\n2. Coverage Criteriaa, b:\nA. Authorization\n1. Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity or Victoza will be\napproved based on one the follo",
    "proved for the treatment of weight\nloss.\n2. Coverage Criteriaa, b:\nA. Authorization\n1. Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity or Victoza will be\napproved based on one the following criteria:\na. Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes\nmellitus as evidenced by one of the following laboratory values\n1) A1C greater than or equal to 6.5%\n2) Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL\n3) 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose\ntolerance test\n© 2025 UnitedHealthcare Services, Inc.\n1\n4) Random plasma glucose >/= 200 mg/dL in patient with classic symptoms of\nhyperglycemia or hyperglycemic crisis\n-OR-\nb. For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed\ngreater than 2 years ago), submission of medical records (e.g. chart notes) confirming\ndiagnosis of type 2 diabetes mellitus\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\nb Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza are not FDA approved\nfor the treatment of weight loss. Medications used for the purposes of weight loss are typically\nexcluded from benefit coverage. Coverage is determined by the member’s prescription drug\nbenefit plan.\nAuthorization will be issued for 12 months.\nBrand Victoza is typically excluded from coverage.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Byetta [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November ",
    " re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Byetta [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2024.\n2. Bydureon BCise [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November\n2024.\n3. Mounjaro [package insert] Indianapolis, IN: Eli Lilly and Company; November 2024.\n4. Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; January 2025.\n5. Rybelsus [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; December2024.\n6. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; November 2024.\n7. Victoza [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; February 2025.\n8. American Diabetes Association. Standard of Medical Care in Diabetes - 2025. Diabetes Care\n2025;48 (Supplement 1).\n9. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a\nDiabetes Mellitus Comprehensive Care Plan - 2022 Update. AACE Clinical Practice Guidelines.\nEndocr Pract. 2022;28: 923-1049\nProgram Prior Authorization/Notification: Diabetes Medications – GLP-1\nReceptor Agonists\nChange Control\n10/2020 New program.\n© 2025 UnitedHealthcare Services, Inc.\n2\n3/2021 Administrative change to adjust Oxford effective date.\n11/2021 Annual review. Updated references.\n9/2022 Updated criteria to define accepted laboratory testing methodologies per\ntreatment guidelines for diagnosis of diabetes and use is not solely for\nweight loss. Updated references. Added state mandate footnote.\n5/2023 Review. Removed Adlyxin & Bydureon. Added Mounjaro. Added\nmedical record requirement for diagnosis of type 2 diabetes. Separated\ncriteria for existing and new diagnosis for diabetes.\n4/2024 Added additional laboratory value. Removed that step therapy may be\nin place. Updated references.\n4/2025 Annual review – updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}